Annovis Bio Promotes Dr. Cheng Fang to Chief Scientific Officer

Annovis Bio (NYSE: ANVS) has promoted Dr. Cheng Fang to chief scientific officer, a strategic move as the company prepares for pivotal milestones in its Alzheimer's disease program. Fang, who joined Annovis in 2021 and most recently served as senior vice president of research and development, will now oversee the company's scientific strategy and research operations across its Alzheimer's and Parkinson's disease pipelines. This includes leading translational science, clinical development, biomarker strategy, and regulatory interactions. The promotion comes at a critical time as Annovis advances its lead drug candidate, buntanetap, toward top-line data from its Phase 3 Alzheimer's disease study and a subsequent New Drug Application submission. Fang has been instrumental in advancing the company's clinical development efforts and will now guide its scientific direction through these upcoming milestones.

Based in Malvern, Pennsylvania, Annovis Bio is a Phase 3 clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The company's lead investigational therapy, buntanetap (formerly posiphen), is a once-daily oral drug that inhibits the translation of multiple neurotoxic proteins—including APP, amyloid beta, tau, alpha-synuclein, and TDP-43—through a specific RNA-targeting mechanism. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The company's progress is closely watched by investors and the medical community, given the urgent need for effective treatments for these devastating conditions.

For more details, readers can access the full press release at https://ibn.fm/c9jdt. Additionally, Annovis maintains a newsroom for the latest updates at https://ibn.fm/ANVS. The company encourages following its progress on LinkedIn and other social channels. This promotion underscores Annovis's commitment to advancing its clinical programs and preparing for regulatory success.